Pricing is increasing for makers of copycat medicines Continue reading...

Moody's Investors Service ("Moody's") downgraded the first lien senior secured ratings of Endo Luxembourg Finance I Company S.à.r.l. Moody's also assigned a B2 rating to the proposed 1st lien secured notes being issued by Par Pharmaceuticals, Inc., a subsidiary of Endo, and a Caa2 rating to 2nd lien secured notes and new unsecured notes being issued by Endo Finance LLC. The new 1st and 2nd lien secured notes will have the same upstream and downstream guarantees as Endo's other secured debt.

Merger arbitrage specialist releases first-quarter portfolio Continue reading...

Endo International plc Announces Proposed Exchange Offers And Consent Solicitations

Q1 2020 Endo International PLC Earnings Call

Endo to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference

At this time, I would like to welcome everyone to the Q1 2020 Endo International earnings conference call. Joining me on today's call are Blaise Coleman, president and CEO of Endo; Mark Bradley, executive vice president and CFO; and Pat Barry, president, global commercial operations; and Domenic Ciarico, chief commercial officer of sterile injectables and generics.

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]

Shares of Endo International (NASDAQ:ENDP) rose 1.1% after the company reported Q1 results.Quarterly Results Earnings per share were up 79.25% year over year to $0.95, which beat the estimate of $0.53.Revenue of $820,405,000 higher by 13.88% from the same period last year, which beat the estimate of $707,650,000.Guidance Endo International hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 07, 2020View more earnings on ENDPTime: 05:02 PM ETWebcast URL: https://edge.media-server.com/mmc/p/kk3vi2nqTechnicals Company's 52-week high was at $8.5552-week low: $1.97Price action over last quarter: down 20.07%Company Overview After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The acquisitions of Auxilium and Par increased the company's presence in urology and generics, respectively.See more from Benzinga * Newmark Group: Q1 Earnings Insights * Cooper Tire & Rubber: Q1 Earnings Insights * Recap: Suburban Propane Partners Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Endo Reports First-Quarter 2020 Financial Results and Provides Update Relating to COVID-19 Pandemic

The sprawling litigation brought by state and local governments seeking to hold drugmakers and distributors responsible for the opioid crisis was supposed to be mostly settled by now. Then Covid-19 happened.

The drugmaker easily beat revenue and earnings estimates with a big jump in sterile injectables sales.

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Endo to Announce First Quarter 2020 Financial Results

Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic

Shares of generic drug makers have been pounded in recent years, pressured by lawsuits over the opioid crisis, falling prices for medicines, and other worries. Fadia argued that generic-drug pricing could rise in the short term due to scarcity created by supply-chain disruptions, and that in the long term, consumers might be willing to pay higher prices for a more secure supply. To that end, she argued, the Covid-19 crisis could result in generic drug makers bringing manufacturing back to the U.S. from India and China, where it is heavily concentrated.

Endo (ENDP) delivered earnings and revenue surprises of 75.93% and 14.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

A billion-dollar market opportunity exists for an opioid manufacturer plagued with lawsuits, but will it be enough for a comeback?